Business Context and Reporting Period
Company: Nektar Therapeutics
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2007
Business Overview: Nektar is a biopharmaceutical company utilizing Pulmonary and PEGylation technology platforms. The company relies heavily on partnerships, most notably with Pfizer for the manufacturing and supply of Exubera (inhaled insulin). As of June 30, 2007, the company had 91,987,765 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2007 |
Six Months Ended June 30, 2007 |
Six Months Ended June 30, 2006 |
|---|---|---|---|
| Total Revenue | $65,917 | $150,933 | $89,182 |
| Net Loss | $(27,510) | $(53,183) | $(96,302) |
| Net Loss Per Share (Basic/Diluted) | $(0.30) | $(0.58) | $(1.08) |
| Cash and Cash Equivalents | $82,856 | $82,856 | $151,989 |
| Total Investments (Short & Long Term) | $323,933 | $323,933 | $403,217 |
| Total Indebtedness | $410,300 | $410,300 | N/A |
| Net Cash Used in Operating Activities | N/A | $(14,687) | $(71,462) |
Note: Total Indebtedness includes $381.6 million in convertible subordinated notes, $20.1 million in capital lease obligations, and $8.6 million in other long-term liabilities.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 69% year-over-year for the six-month period ($150.9M vs. $89.2M). This was primarily driven by a >100% increase in product sales and royalties ($122.3M vs. $60.0M), largely due to increased Exubera shipments and a change in revenue recognition policy.
- Revenue Recognition Change: Effective January 1, 2007, the company began recognizing Exubera revenue upon shipment rather than deferring it for 60 days. This change accelerated revenue recognition, contributing approximately $45.6 million to the six-month revenue increase.
- Improved Loss Position: Net loss for the six months ended June 30, 2007, decreased significantly to $53.2 million compared to $96.3 million in the prior year period. This improvement is attributed to higher revenues and the absence of a $17.7 million litigation settlement charge recorded in the prior year.
- Workforce Reduction: In May 2007, the company initiated a plan to reduce its workforce by approximately 25% (180 employees), incurring $7.7 million in charges during the quarter, with an expected total cost of $8.5 million.
- Debt Repayment: The company repaid $36.0 million of its 5% convertible subordinated notes in February 2007.
Guidance, Outlook, and Risks
- Revenue Outlook: Management anticipates that total revenue and product sales will be lower in the second half of 2007 and significantly lower in fiscal year 2008 compared to 2007. This is due to reduced Exubera manufacturing volumes necessitated by Pfizer's inventory buildup and slower-than-expected commercial sales.
- New Partnership: On August 1, 2007 (subsequent to the period end), Nektar entered into a co-development agreement with Bayer Healthcare for NKTR-061 (inhaled amikacin). The deal includes a $50 million upfront payment and up to $175 million in milestone payments.
- Liquidity and Debt: The company has approximately $406.8 million in cash and investments against $410.3 million in indebtedness. A significant portion of cash will be used to fund operations and repay $66.6 million in convertible notes due in October 2007.
- Key Risks:
- Pfizer Dependence: Pfizer represented 66% to 72% of total revenue. The commercial success of Exubera is entirely dependent on Pfizer's marketing and sales efforts, which have been slower than anticipated.
- Manufacturing Volatility: Fluctuations in Exubera demand could lead to capacity reduction expenses or require significant capital investment to expand capacity.
- Regulatory and Litigation: Risks include potential side effects of Exubera, regulatory inspections, and ongoing litigation regarding patent infringement (Novo Nordisk vs. Pfizer) which could impact indemnity obligations.
Investor Verification Checklist
- Exubera Sales Velocity: Verify Pfizer's actual sales data and inventory levels for Exubera to assess the validity of Nektar's reduced revenue guidance for late 2007 and 2008.
- Debt Maturity Wall: Confirm the company's ability to refinance or repay the $66.6 million convertible note due in October 2007 given the current cash burn rate.
- Workforce Reduction Impact: Monitor the execution of the 25% workforce reduction plan and the resulting impact on R&D timelines and operational efficiency.
- Bayer Deal Terms: Review the full terms of the August 1, 2007 agreement with Bayer, specifically the conditions for the $50 million upfront payment and the $175 million in milestones.
- Revenue Recognition Policy: Understand the long-term implications of the shift to recognizing Exubera revenue upon shipment versus the previous 60-day deferral.